Although primary prophylaxis with granulocyte colony-stimulating factor (G-CSF) was not recommended in early clinical trials, it was used as secondary prophylaxis in patients who subsequently developed neutropenia [31,39]. This evidence concerns the gene CSF3 and neutropenia.